<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mexiletine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mexiletine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mexiletine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9648" href="/d/html/9648.html" rel="external">see "Mexiletine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11393" href="/d/html/11393.html" rel="external">see "Mexiletine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709085"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Mortality:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">In the National Heart, Lung, and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non–life-threatening ventricular arrhythmias who had an myocardial infarction (MI) more than 6 days but less than 2 years previously, an excessive mortality or nonfatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3%). The average duration of treatment with encainide or flecainide in this study was 10 months.</p>
<p style="text-indent:0em;">The applicability of the CAST results to other populations (eg, those without recent MI) is uncertain. Considering the known proarrhythmic properties of mexiletine and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of mexiletine as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Acute liver injury:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">In postmarketing experience, abnormal liver function tests have been reported, some in the first few weeks of therapy with mexiletine. Most of these have been observed in the setting of congestive heart failure or ischemia and their relationship to mexiletine has not been established.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867550"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>TEVA-Mexiletine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1054050"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiarrhythmic Agent, Class I-B</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812534"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7788e714-fc48-4013-8723-fd5592171025">Ventricular arrhythmias; life-threatening, including Long QT Syndrome Type 3</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular arrhythmias; life-threatening, including Long QT Syndrome Type 3:</b> Limited data available: Children and Adolescents: Oral: Initial: 6 to 8 mg/kg/<b>day</b> in 2 or 3 divided doses for 2 to 3 days, then increase to 2 to 5 mg/kg/dose every 8 to 12 hours; continue to increase by 1 to 2 mg/kg/dose every 2 to 3 days until desired effect; monitor serum concentrations. Maximum daily dose: 15 mg/kg/<b>day</b> or 1,200 mg/<b>day</b> whichever is less. Based on experience in adult patients, do not exceed the maximum single adult doses of: 400 mg every 8 hours, or 450 mg every 12 hours. In a study of 34 patients (median age: 22 years; IQR: 8 to 44 years) with Long QT syndrome Type 3, a mean dose of 8 ± 0.5 mg/kg/day induced significant shortening of the QTc interval; and 59% of patients exhibited normalization QTC values with mexiletine therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-26940925','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-26940925','lexi-content-ref-Park.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729776"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, no adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F52729777"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Based on experience in adult patients with hepatic impairment or hepatic congestion secondary to heart failure, dosing adjustment suggested; half-life is approximately doubled in adult patients with hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F196177"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9648" href="/d/html/9648.html" rel="external">see "Mexiletine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0f955356-c9c5-4353-8681-3e0d991623cb">Amyotrophic lateral sclerosis, painful muscle spasms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amyotrophic lateral sclerosis, painful muscle spasms (off-label use):</b> Initial: 150 mg once daily for 3 days, then increase dose to 150 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29510461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29510461'])">Ref</a></span>). Alternatively, doses up to 450 mg twice daily have been initiated, though higher initial dosing leads to decreased drug tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26911633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26911633'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1e9f42e-e299-4691-91da-5d00842bf90f">Myotonic dystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myotonic dystrophy (type 1) (off-label use):</b>
<b>Oral:</b> 150 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20439846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20439846'])">Ref</a></span>). <b>Note:</b> It is prudent to obtain a cardiology consult prior to beginning therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f42c553-e8c4-4b54-98fb-e270b999dc6b">Ventricular arrhythmias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular arrhythmias (life-threatening): Oral:</b> Initial: 150 to 200 mg every 8 to 12 hours (may load with 400 mg if necessary); adjust dose as needed in 50 or 100 mg increments no more frequently than every 2 to 3 days up to 300 mg every 8 to 12 hours; usual dose: 150 to 300 mg every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>); maximum dose: 1.2 g/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Conversion: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Switching from other oral antiarrhythmics (eg, disopyramide, quinidine sulfate):</i> Initiate 200 mg dose of mexiletine 6 to 12 hours after the last dose of the former agent.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Switching from IV lidocaine:</i> Initiate 200 mg dose of mexiletine when lidocaine infusion is stopped.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Switching from oral procainamide:</i> Initiate a 200 mg dose of mexiletine 3 to 6 hours after the last dose of procainamide.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8836792b-e6db-479e-b31a-15b29119dca4">Ventricular premature beat suppression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular premature beat (symptomatic) suppression (off-label use):</b>
<b>Oral:</b> Initial: 100 to 150 mg every 8 to 12 hours; adjust dose as needed in 50 or 100 mg increments no more frequently than every 2 to 3 days up to 300 mg every 8 to 12 hours; usual dose: 150 to 300 mg every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-4031292','lexi-content-ref-1283888','lexi-content-ref-1724233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-4031292','lexi-content-ref-1283888','lexi-content-ref-1724233'])">Ref</a></span>); maximum dose: 1.2 g/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990244"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7126416','lexi-content-ref-4006364','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7126416','lexi-content-ref-4006364','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4006364','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4006364','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not significantly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4027132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4027132'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987379"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Patients with hepatic impairment or hepatic congestion secondary to heart failure may require dose reduction; half-life is approximately doubled in patients with hepatic impairment.</p></div>
<div class="block adr drugH1Div" id="F196144"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Exacerbation of cardiac arrhythmia (10% to 15%; patients with malignant arrhythmia)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (11% to 25%), ataxia (10% to 20%), nervousness (5% to 10%), unsteady gait</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal distress (41%), nausea (≤40%), vomiting (≤40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitations (4% to 8%), chest pain (3% to 8%), angina pectoris (2%), ventricular premature contractions (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Insomnia (5% to 7%), numbness (fingers or toes: 2% to 4%), depression (2%), paresthesia (2%), confusion, headache</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (≤5%), diarrhea (≤5%), xerostomia (3%), abdominal pain (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (5%), arthralgia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (5% to 7%), nystagmus (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, alopecia, amnesia (short-term), atrioventricular block, cardiac conduction disturbance, cardiac failure (patients with pre-existing ventricular dysfunction), cardiogenic shock, decreased libido, diaphoresis, diplopia, dysphagia, edema, esophageal ulcer, exfoliative dermatitis, hallucination, hepatic necrosis, hepatitis, hot flash, hypertension, hypotension, impotence, increased liver enzymes, increased serum transaminases, leukopenia, lupus-like syndrome (drug-induced), malaise, myelofibrosis (patients with pre-existing myeloid abnormalities), pancreatitis (rare), peptic ulcer, pharyngitis, positive ANA titer, psychological disorder, psychosis, pulmonary fibrosis, salivary gland disease, seizure, sinoatrial arrest, Stevens-Johnson syndrome, syncope, thrombocytopenia, torsades de pointes, upper gastrointestinal hemorrhage, urinary hesitancy, urinary retention, urticaria</p></div>
<div class="block coi drugH1Div" id="F196158"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Cardiogenic shock; second- or third-degree AV block (except in patients with a functioning artificial pacemaker)</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): Hypersensitivity to mexiletine, amide-type local anesthetics (eg, pramoxine), or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F196141"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood dyscrasias: Rare marked leukopenia, agranulocytosis, and thrombocytopenia have been reported; often occurs in seriously ill patients receiving other medications that can cause these effects. If significant hematologic changes occur, discontinue therapy (blood counts usually return to normal within a month of discontinuation).</p>
<p style="text-indent:-2em;margin-left:4em;">• Drug reactions with eosinophilia and systemic symptoms: Drug reactions with eosinophilia and systemic symptoms (DRESS) has been reported. Discontinue if DRESS is suspected. Symptoms of DRESS include eosinophilia, fever, rash, and/or lymphadenopathy in association with other organ involvement, such as hepatitis, nephritis, hematologic abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity:<b> [US Boxed Warning]: Abnormal liver function tests have been reported, some in the first few weeks of therapy. Most of these have been observed in the setting of congestive heart failure or ischemia and their relationship to mexiletine has not been established.</b> Marked elevations of AST (&gt;1000 units/L) and rare instances of severe liver injury, including hepatic necrosis, have also been reported. Carefully monitor patients who develop abnormal LFTs or who have signs/symptoms of liver dysfunction. If persistent or worsening elevation of hepatic enzymes occurs, consider discontinuing therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Proarrhythmic effects: Proarrhythmia may occur with the use of mexiletine especially in those with life-threatening arrhythmias (eg, sustained ventricular tachycardia). Aggravation of arrhythmia may also occur; monitor for proarrhythmic effects (Podrid 1987; Podrid 1999; Velebit 1982).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Conduction disturbances: Use with caution in patients with intraventricular conduction delays, first-degree heart block and/or preexisting sinus node dysfunction. Use is contraindicated in patients with second- or third-degree AV block (except in patients with a functioning artificial pacemaker).</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy (Podrid 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure (HF): Use with caution in patients with severe HF; may precipitate or exacerbate condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; may prolong the elimination half-life of mexiletine and increase the risk of adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure: Use with caution in patients with seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Initiate therapy in the hospital when used to treat life-threatening arrhythmias. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Has not been shown to enhance survival in patients with ventricular arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• CAST trial:<b> [US Boxed Warning]: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, nonlife-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.</b> In a double-blind placebo controlled trial in patients with recent MI, the use of mexiletine to reduce premature ventricular contractions demonstrated a numerically greater number of deaths compared to placebo (IMPACT Research Group, 1984).</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary pH: Alterations in urinary pH may change urinary excretion; avoid dietary regimens that may markedly alter urinary pH.</p></div>
<div class="block foc drugH1Div" id="F196151"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg, 200 mg, 250 mg</p></div>
<div class="block geq drugH1Div" id="F196137"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F196160"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Mexiletine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $1.46 - $2.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1.69 - $3.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $2.43 - $3.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867551"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg</p></div>
<div class="block exp drugH1Div" id="F11429744"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 10 mg/mL oral suspension may be with made with capsules and either distilled water or sorbitol USP. Empty the contents of eight 150 mg capsules in a mortar and reduce to a fine powder if necessary. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label "shake well". Sorbitol suspension is stable in plastic prescription bottles for 2 weeks at room temperature and 4 weeks refrigerated; distilled water suspension is stable in plastic prescription bottles for 7 weeks at room temperature and 13 weeks refrigerated. Extended storage under refrigeration is recommended to minimize microbial contamination.</p>
<div class="reference">Nahata MC, Morosco RS, and Hipple TF, "Stability of Mexiletine in Two Extemporaneous Liquid Formulations Stored Under Refrigeration and at Room Temperature," <i>J Am Pharm Assoc (Wash)</i>, 2000, 40(2):257-9.<span class="pubmed-id">10730027</span></div>
</div>
<div class="block admp drugH1Div" id="F52613325"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer around-the-clock (every 8 or 12 hours) rather than 2 or 3 times daily to promote less variation in peak and trough serum levels; administer with food or antacid</p></div>
<div class="block adm drugH1Div" id="F196155"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer around-the-clock rather than 3 times daily to promote less variation in peak and trough serum levels; administer with food or antacid</p></div>
<div class="block sts drugH1Div" id="F28744606"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53567840"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Management of life-threatening ventricular arrhythmias (FDA approved in adults)</p></div>
<div class="block cyt drugH1Div" id="F196212"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major), CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (moderate)</p></div>
<div class="block dri drugH1Div" id="F196146"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agomelatine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Agomelatine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Alosetron.  Management: Avoid concomitant use of alosetron and moderate CYP1A2 inhibitors whenever possible. If combined use is necessary, monitor for increased alosetron effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: CYP1A2 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Anagrelide. CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Anagrelide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May increase the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bendamustine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Bendamustine.  Management: Consider alternatives to moderate CYP1A2 inhibitors during therapy with bendamustine due to the potential for increased bendamustine plasma concentrations and increased bendamustine toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromazepam: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Bromazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Caffeine and Caffeine Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Moderate): May decrease the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May decrease the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Mexiletine may enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Topical): May enhance the adverse/toxic effect of Antiarrhythmic Agents (Class IB).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pentoxifylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: Avoid concomitant use of pirfenidone and moderate CYP1A2 inhibitors whenever possible. If combined, decrease the pirfenidone dose to 1,602 mg per day (534 mg three times daily) and monitor for increased pirfenidone toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pomalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: May increase the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Rasagiline.  Management: Limit rasagiline dose to 0.5 mg once daily in patients taking moderate CYP1A2 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPivacaine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ROPivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: May increase the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Theophylline Derivatives.  Management: Consider avoidance of this combination. If coadministration is necessary, monitor for increased theophylline serum concentrations and toxicities when combined. Theophylline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of TiZANidine.  Management: If combined use cannot be avoided, initiate tizanidine in adults at 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Mexiletine.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F196169"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food may decrease the rate, but not the extent of oral absorption; diets which affect urine pH can increase or decrease excretion of mexiletine. Management: Avoid dietary changes that alter urine pH.</p></div>
<div class="block pri drugH1Div" id="F14206276"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in some animal reproduction studies. A few case reports have demonstrated safe use of mexiletine in pregnant women (Gregg 1988; Lownes 1987; Timmis 1980).</p></div>
<div class="block mopp drugH1Div" id="F53567836"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver enzymes, CBC, ECG, heart rate, serum concentrations</p></div>
<div class="block rerp drugH1Div" id="F53567689"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic range:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: 0.75 to 2 mcg/mL (Park 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.5 to 2 mcg/mL</p>
<p style="text-indent:-2em;margin-left:2em;">Potentially toxic: &gt;2 mcg/mL</p></div>
<div class="block pha drugH1Div" id="F196140"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Class IB antiarrhythmic, structurally related to lidocaine, which inhibits inward sodium current, decreases rate of rise of phase 0, increases effective refractory period/action potential duration ratio</p></div>
<div class="block phk drugH1Div" id="F196157"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: 30 to 120 minutes (with loading regimen)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 5 to 7 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 50% to 60% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via CYP2D6 metabolism to inactive metabolites (~90%) and major metabolites p-hydroxymexiletine, hydroxy-methylmexiletine,  and N-hydroxy-mexiletine (minimal antiarrhythmic activity); low first-pass effect </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 90%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~10 to 12 hours; ~ 15 hours in severe renal impairment (CrCl &lt; 10 ml/min); ~ 25 hours in moderate to severe hepatic impairment  </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 2 to 3 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (10% as unchanged drug); urinary acidification increases excretion, alkalinization decreases excretion</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038680"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Mexitilen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Mexitil | Namuscla</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Katen | Mexitil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Katen | Mexitil</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Mexihexal | Mexitil | Namuscla</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mexitil | Ritalmex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Mexitil | Namuscla</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Mexiletine ap hp | Mexiletine Dci | Mexitil | Namuscla</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mexitil | Namuscla | Ritalmex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Antiaril | Mexiletine | Mexitil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Mexitil | Ritalmex</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Mexitec</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Mexiletine | Mexitil</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Mexilen</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Mexitil | Mexohar | Welhart</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cirumimeru | Hystatiel | Mekiratin | Melate | Meldest | Meldest taiyo | Mequitolide | Merest | Meriate | Metorekicin | Mexibal | Mexitil | Mobalen | Olzoron | Poeruten</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bumac | Mexilen | Mexitil</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Katen | Mexitil | Namuscla</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Katen | Mexitil</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Mexiletine | Mexitil | Namuscla</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Mexiletine | Mexitil</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Katen | Mexiletine HCL | Mexitil | Novo-mexiletine | Ritalmex</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Mexiletine HCL | Mexitil</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Mexitil | Ritalmex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Mexitil | Namuscla</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Mexitil | Namuscla | Ritalmex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Katen</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Mexitil | Ritalmex</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Meletin | Mesyn | Mexitil | Mugadine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Katen | Mexaritm | Mexitil | Ritalmex</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Mexitilen</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Tumetil</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Mexitil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published online October 30, 2017]. <i>Circulation</i>. doi: 10.1161/CIR.0000000000000549.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1900101">
<a name="1900101"></a>Echt DS, Liebson PR, Mitchell LB, et al, “Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial,” <i>N Engl J Med</i>, 1991, 324(12):781-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/1900101/pubmed" id="1900101" target="_blank">1900101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7126416">
<a name="7126416"></a>El Allaf D, Henrard L, Crochelet L, Delapierre D, Carlier J, Dresse A. Pharmacokinetics of mexiletine in renal insufficiency. <i>Br J Clin Pharmacol.</i> 1982;14(3):431-435. doi:10.1111/j.1365-2125.1982.tb02003.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/7126416/pubmed" id="7126416" target="_blank">7126416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26320108">
<a name="26320108"></a>ESC Guidelines for the management of patients with ventricular arrythmias and the prevention of sudden cardiac death. <i>European Heart Journal</i>. 2015:36;2793-2867.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/26320108/pubmed" id="26320108" target="_blank">26320108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1512329">
<a name="1512329"></a>Flaker GC, Blackshear JL, McBride R, et al, “Antiarrhythmic Drug Therapy and Cardiac Mortality in Atrial Fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators,” <i>J Am Coll Cardiol</i>, 1992, 20:527-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/1512329/pubmed" id="1512329" target="_blank">1512329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3236091">
<a name="3236091"></a>Gregg AR, Tomich PG. Mexiletine use in pregnancy. <i>J Perinatol</i>. 1988;8(1):33-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/3236091/pubmed" id="3236091" target="_blank">3236091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4027132">
<a name="4027132"></a>Guay DR, Meatherall RC, Ferguson I, Smith H, Light B. Mexiletine clearance during peritoneal dialysis. <i>Br J Clin Pharmacol.</i> 1985;19(6):857-858. doi:10.1111/j.1365-2125.1985.tb02732.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/4027132/pubmed" id="4027132" target="_blank">4027132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6209318">
<a name="6209318"></a>Impact Research Group. International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. <i>J Am Coll Cardiol</i>. 1984;4(6):1148-1163.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/6209318/pubmed" id="6209318" target="_blank">6209318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20439846">
<a name="20439846"></a>Logigian EL, Martens WB, Moxley RT 4th, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. <i>Neurology</i>. 2010;74(18):1441-1448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/20439846/pubmed" id="20439846" target="_blank">20439846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3618696">
<a name="3618696"></a>Lownes HE, Ives TJ. Mexiletine use in pregnancy and lactation. <i>Am J Obstet Gynecol</i>. 1987;157(2):446-447.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/3618696/pubmed" id="3618696" target="_blank">3618696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manolis.2018">
<a name="Manolis.2018"></a>Manolis AS. Ventricular premature beats. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 26, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26940925">
<a name="26940925"></a>Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. <i>J Am Coll Cardiol.</i> 2016;8;67(9):1053-1058. doi: 10.1016/j.jacc.2015.12.033.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/26940925/pubmed" id="26940925" target="_blank">26940925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ingenus.1">
<a name="Ingenus.1"></a>Mexiletine hydrochloride [prescribing information]. Orlando, FL: Ingenus Pharmaceuticals, LLC; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MINT-Mexiletine.1">
<a name="MINT-Mexiletine.1"></a>MINT-Mexiletine capsules, USP [product monograph]. Mississauga, Ontario, Canada: Mint Pharmaceuticals Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3655149">
<a name="3655149"></a>Moak JP, Smith RT, and Garson A Jr, “Mexiletine: An Effective Antiarrhythmic Drug for Treatment of Ventricular Arrhythmias in Congenital Heart Disease,” <i>J Am Coll Cardiol</i>, 1987, 10(4):824-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/3655149/pubmed" id="3655149" target="_blank">3655149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29510461">
<a name="29510461"></a>Oskarsson B, Moore D, Mozaffar T, et al. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial. <i>Muscle Nerve.</i> 2018. doi: 10.1002/mus.26117.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/29510461/pubmed" id="29510461" target="_blank">29510461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2437788">
<a name="2437788"></a>Podrid PJ, Lampert S, Graboys TB, Blatt CM, Lown B. Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors. <i>Am J Cardiol</i>. 1987;59(11):38E-44E.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/2437788/pubmed" id="2437788" target="_blank">2437788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10980856">
<a name="10980856"></a>Podrid PJ. Proarrhythmia, a serious complication of antiarrhythmic drugs. <i>Curr Cardiol Rep</i>. 1999;1(4):289-296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/10980856/pubmed" id="10980856" target="_blank">10980856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4031292">
<a name="4031292"></a>Rutledge JC, Harris F, Amsterdam EA. Clinical evaluation of oral mexiletine therapy in the treatment of ventricular arrhythmias. <i>J Am Coll Cardiol</i>. 1985;6(4):780-784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/4031292/pubmed" id="4031292" target="_blank">4031292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1283888">
<a name="1283888"></a>Saikawa T, Nakagawa M, Takahashi N, et al. Mexiletine and disopyramide suppress ventricular premature contractions (VPC) irrespective of the relationship between the VPC and the underlying heart rate. <i>Jpn Heart J</i>. 1992;33(5):665-678.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/1283888/pubmed" id="1283888" target="_blank">1283888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1724643">
<a name="1724643"></a>Strasburger JF. Cardiac arrhythmias in childhood. Diagnostic considerations and treatment. <i>Drugs</i>. 1991;42(6):974-983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/1724643/pubmed" id="1724643" target="_blank">1724643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1724233">
<a name="1724233"></a>Tanabe T, Takahaski K, Yoshioka K, Goto Y. Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease. <i>Int J Cardiol</i>. 1991;32(3):303-312.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/1724233/pubmed" id="1724233" target="_blank">1724233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TevaCan.1">
<a name="TevaCan.1"></a>Teva-Mexiletine [product monograph]. Toronto, Ontario, Canada: Teva Canada Ltd; July 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6107439">
<a name="6107439"></a>Timmis AD, Jackson G, Holt DW. Mexiletine for control of ventricular dysrhythmias in pregnancy. <i>Lancet</i>. 1980;2(8195 pt 1):647-648.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/6107439/pubmed" id="6107439" target="_blank">6107439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6176355">
<a name="6176355"></a>Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. <i>Circulation.</i> 1982;65(5):886-894.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/6176355/pubmed" id="6176355" target="_blank">6176355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4006364">
<a name="4006364"></a>Wang T, Wuellner D, Woosley RL, Stone WJ. Pharmacokinetics and nondialyzability of mexiletine in renal failure. <i>Clin Pharmacol Ther.</i> 1985;37(6):649-653. doi:10.1038/clpt.1985.105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/4006364/pubmed" id="4006364" target="_blank">4006364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26911633">
<a name="26911633"></a>Weiss MD, Macklin EA, Simmons Z, et al; Mexiletine ALS Study Group. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. <i>Neurology</i>. 2016;86(16):1474-1481. doi: 10.1212/WNL.0000000000002507.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mexiletine-pediatric-drug-information/abstract-text/26911633/pubmed" id="26911633" target="_blank">26911633</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12608 Version 275.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
